Curis Lifesciences Limited (NSE:CURIS)
India · Delayed Price · Currency is INR 207.00
0.00 (0.00%)
At close: Oct 5, 2026
Curis Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Other Revenue | 0 | -0 | - | - | - |
| 606.29 | 502.59 | 355.56 | 354.49 | 237.45 | |
Revenue Growth | 20.63% | 41.35% | 0.30% | 49.29% | 11.69% |
Cost of Revenue | 420 | 319.56 | 231.25 | 283.96 | 157.83 |
Gross Profit | 186.29 | 183.02 | 124.31 | 70.53 | 79.63 |
Selling, General & Admin | 36.17 | 32.29 | 40.41 | 37.67 | 43.81 |
Other Operating Expenses | 37.65 | 43.3 | -0.02 | -6.24 | - |
Operating Expenses | 81.95 | 82.33 | 47.2 | 38.74 | 51.36 |
Operating Income | 104.34 | 100.69 | 77.11 | 31.8 | 28.26 |
Interest Expense | -11.39 | -11.06 | -8.49 | -13.28 | -16.16 |
Interest & Investment Income | 2.5 | 0.11 | 3.12 | 3.27 | 0.12 |
Other Non Operating Income (Expenses) | 0.31 | 0.01 | -0 | 0 | 0 |
EBT Excluding Unusual Items | 95.76 | 89.76 | 71.73 | 21.79 | 12.22 |
Gain (Loss) on Sale of Assets | - | - | - | 0.11 | 0.05 |
Other Unusual Items | -0.15 | 0.12 | - | - | - |
Pretax Income | 95.62 | 89.88 | 71.73 | 21.9 | 12.27 |
Income Tax Expense | 26.45 | 27.82 | 23.06 | 3.15 | 7.34 |
Net Income | 69.16 | 62.06 | 48.67 | 18.75 | 4.92 |
Preferred Dividends & Other Adjustments | 0.35 | - | - | - | - |
Net Income to Common | 68.81 | 62.06 | 48.67 | 18.75 | 4.92 |
Net Income Growth | 10.87% | 27.52% | 159.53% | 280.85% | -3.17% |
Shares Outstanding (Basic) | 2 | 2 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 2 | 2 | 6 | 6 | 6 |
Shares Change | - | -68.57% | - | 7.18% | - |
EPS (Basic) | 37.14 | 33.50 | 8.26 | 3.18 | 0.90 |
EPS (Diluted) | 37.14 | 33.50 | 8.26 | 3.18 | 0.90 |
EPS Growth | 10.87% | 305.70% | 159.53% | 255.33% | -3.17% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -182.18 | -21.25 | 2.07 | 27.31 | 45.47 |
Free Cash Flow Per Share | -98.32 | -11.47 | 0.35 | 4.63 | 8.27 |
Gross Margin | 30.73% | 36.42% | 34.96% | 19.90% | 33.53% |
Operating Margin | 17.21% | 20.04% | 21.69% | 8.97% | 11.90% |
Profit Margin | 11.35% | 12.35% | 13.69% | 5.29% | 2.07% |
Free Cash Flow Margin | -30.05% | -4.23% | 0.58% | 7.70% | 19.15% |
EBITDA | 111.3 | 107.44 | 83.9 | 39.06 | 35.81 |
EBITDA Margin | 18.36% | 21.38% | 23.60% | 11.02% | 15.08% |
D&A For EBITDA | 6.96 | 6.75 | 6.79 | 7.26 | 7.55 |
EBIT | 104.34 | 100.69 | 77.11 | 31.8 | 28.26 |
EBIT Margin | 17.21% | 20.04% | 21.69% | 8.97% | 11.90% |
Effective Tax Rate | 27.67% | 30.95% | 32.15% | 14.38% | 59.86% |
Revenue as Reported | 609.1 | 502.71 | 358.7 | 364.17 | 237.62 |
Advertising Expenses | - | - | - | 0.67 | - |